Aarsland, D., Litvan, I., Salmon, D., Galasko, D., Wentzel-Larsen, T. and Larsen, J. P. (2003). Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 74, 1215–1220.CrossRefGoogle ScholarPubMed

Aarsland, D., Ballard, C. G. and Halliday, G. (2004). Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? Journal of Geriatric Psychiatry and Neurology, 17, 137–145.CrossRefGoogle ScholarPubMed

Aarsland, D. et al. (2005a). Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Journal of Clinical Psychiatry, 66, 633–637.Google ScholarPubMed

Aarsland, D., Perry, R., Brown, A., Larsen, J. P. and Ballard, C. (2005b). Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Annals of Neurology, 58, 773–776.CrossRefGoogle ScholarPubMed

Ames, D., Ballard, C., Cream, J., Shah, A., Suh, G. H. and McKeith, I. (2005). For debate: should novel antipsychotics ever be used to treat the behavioral and psychological symptoms of dementia (BPSD)? International Psychogeriatrics, 17, 3–29.Google Scholar

Ames, D., Petersen, R. C., Knopman, D. S., Visser, P. J., Brodaty, H. and Gauthier, S. (2006). For debate: is Mild Cognitive Impairment a clinically useful concept? International Psychogeriatrics, 18, 393–414.CrossRefGoogle Scholar

Ames, D. et al. (2007). For debate: is the influence of the pharmaceutical industry on prescribing, research and publication in the field of psychogeriatrics excessive? International Psychogeriatrics, 19, 1003–1020.Google ScholarPubMed

Ames, D., Kaduszkiewicz, H., van den Bussche, H., Zimmermann, T., Birks, J. and Ashby, D. (2008). For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? International Psychogeriatrics, 20, 259–292.CrossRefGoogle ScholarPubMed

Ballard, C. et al. (2001). The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 16, 499–503.CrossRefGoogle ScholarPubMed

Ballard, C. G. et al. (2004). Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. American Journal of Psychiatry, 161, 843–849.Google Scholar

Ballard, C. et al. (2006). Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology, 67, 1931–1934.CrossRefGoogle ScholarPubMed

Beyer, M. K., Larsen, J. P. and Aarsland, D. (2007). Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology, 69, 747–754.Google Scholar

Beyer, K., Domingo-Sabat, M., Humbert, J., Carrato, C., Ferrer, I. and Ariza, A. (2008). Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics, 9, 163–72.CrossRefGoogle ScholarPubMed

Bibl, M. et al. (2006). CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain, 129, 1177–1187.Google Scholar

Bogaerts, V. et al. (2007). A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain, 130, 2277–2291.CrossRefGoogle ScholarPubMed

Bonanni, L., Thomas, A., Tiraboschi, P., Perfetti, B., Varanese, S. and Onofrj, M. (2008). EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain, 131, 690–705.CrossRefGoogle ScholarPubMed

Braak, H., Del Tredici, K., Rub, U., de Vos, R. A. I., Jansen Steur, E. N. H. and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24, 197–211.Google Scholar

Brønnick, K. S., Nordby, H., Larsen, J. P. and Aarsland, D. (2008). Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: a mismatch negativity study. Neurobiology of Aging. doi: 10.1016/j.neurobiolaging.2008.02.021 (epublished ahead of print).Google Scholar

Burn, D. et al. (2006a). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders, 21, 1899–1907.Google Scholar

Burn, D. J., Rowan, E. N., Allan, L. M., Molloy, S., O'Brien, J. T. and McKeith, I. G. (2006b). Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 77, 585–589.Google Scholar

Burton, E. J., McKeith, I. G., Burn, D. J., Williams, E. D. and O'Brien, J. T. (2004). Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 127, 791–800.CrossRefGoogle ScholarPubMed

Calne, D. B. and Mizuno, Y. (2004). The neuromythology of Parkinson's disease. Parkinsonism and Related Disorders, 10, 319–322.CrossRefGoogle ScholarPubMed

Colloby, S. and O'Brien, J. T. (2004). Functional imaging in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology, 17, 158–163.Google Scholar

Colloby, S. J. et al. (2006). In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage, 33, 423–429.CrossRefGoogle Scholar

Downes, J. J., Priestley, N. M., Doran, M., Ferran, J., Ghadiali, E. and Cooper, P. (1998). Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson's disease. Behavioural Neurology, 11, 173–183.Google Scholar

Dubois, R. et al. (2007). Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Movement Disorders, 22, 2314–2324.Google Scholar

Emre, M. et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22, 1689–1707.CrossRefGoogle ScholarPubMed

Ferman, T. J. et al. (2007). Dementia with Lewy Bodies. Neurologic Clinics, 45, 741–750.Google Scholar

Francis, P. T. and Perry, E. K. (2007). Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Movement Disorders, 22 (Suppl. 17), S351–357.CrossRefGoogle ScholarPubMed

Fujishiro, H. et al. (2008). Validation of the neuropathologic criteria of the Third Consortium for Dementia with Lewy Bodies for prospectively diagnosed cases. Journal of Neuropathology and Experimental Neurology, 67, 649–656.Google Scholar

Ganguli, M., Dombrovski, A. Y., Mulsant, B. H., Wilkinson, P., Tharyan, P. and Flint, A. (2007). For debate: the evidence for electroconvulsive therapy (ECT) in the treatment of severe late-life depression. International Psychogeriatrics, 19, 9–35.CrossRefGoogle Scholar

Giasson, B. I. et al. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science, 300, 636–640.Google Scholar

Harding, A. J. and Halliday, G. M. (2001). Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathologica (Berlin), 102, 355–363.Google Scholar

Harding, A. J., Broe, G. A. and Halliday, G. M. (2002). Visual hallucinations in Lewy body disease related to Lewy bodies in the temporal lobe. Brain, 125, 391–403.Google Scholar

Hurtig, H. I. et al. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology, 54, 1916–1921.Google Scholar

Jellinger, K. A., Seppi, K., Wenning, G. K. and Poewe, W. (2002). Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. Journal of Neural Transmission, 109, 329–39.Google Scholar

Kovari, E. et al. (2003). Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathologica (Berlin), 106, 83–88.Google Scholar

Kramer, M. L. and Schulz-Schaeffer, W. J. (2007). Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. Journal of Neuroscience, 27, 1405–1410.CrossRefGoogle Scholar

Kurz, M. W., Schlitter, A. M., Larsen, J. P., Ballard, C. and Aarsland, D. (2006). Familial occurrence of dementia and parkinsonism: a systematic review. Dementia and Geriatric Cognitive Disorders, 22, 288–295.Google Scholar

Lane, R., He, Y., Morris, C., Leverenz, J. B., Empe, M. and Ballard, C. (2008). BuChE-K and APOE ϵ4 allete frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Movement Disorders, doi: 10.1002/mds.22357, e-published ahead of print.Google Scholar

Lashley, T. et al. (2008). Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathologica, 115, 417–425.CrossRefGoogle Scholar

Levy, G. (2007). The relationship of Parkinson disease with aging. Archives Neurology, 64, 1242–1246.Google Scholar

Lippa, C. F. et al. (2007). DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology, 68, 812–819.Google Scholar

Macinnes, N. et al. (2008). Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. Journal of Neural Transmission, 115, 869–878.Google Scholar

Mastaglia, F. L., Johnsen, R. D., Byrnes, M. L. and Kakulas, B. A. (2003). Prevalaence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Movement Disorders, 18, 81–86.Google Scholar

McKeel, D. W. et al. (2004). Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. Journal of Neuropathology and Experimental Neurology, 63, 1028–1037.Google Scholar

McKeith, I. G. et al. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology, 47, 1113–1124.Google Scholar

McKeith, I. G. et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third Report of the DLB Consortium. Neurology, 65, 1863–1872.CrossRefGoogle ScholarPubMed

Merdes, A. R. et al. (2003). Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology, 60, 1586–1590.Google Scholar

Molloy, S. A., Rowan, E. N., O'Brien, J. T., McKeith, I. G., Wesnes, K. and Burn, D. J. (2006). Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 77, 1323–1328.Google Scholar

O'Brien, K. K. et al. (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics, 13, 231–239.Google Scholar

O'Brien, J. T. et al. (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology, 61, 919–925.CrossRefGoogle ScholarPubMed

O'Brien, J. T., Wahlund, L.O., Scheltens, P. and Förstl, H. (2007). For debate: should neuroimaging be a routine investigation in all cases of suspected dementia? International Psychogeriatrics, 19, 525–538.Google Scholar

Parnetti, L. et al. (2008). Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biological Psychiatry, 64, 850–855.Google Scholar

Perry, E., McKeith, I. and Ballard, C. (2003). Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology, 60, 1852–1853.Google Scholar

Piggott, M. A. et al. (1998). Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biological Psychiatry, 44, 765–774.Google Scholar

Piggott, M. A. et al. (1999). Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain, 122, 1449–1468.Google Scholar

Revuelta, G. J., Rosso, A. and Lippa, C. F. (2008). Neuritic pathology as a correlate for synaptic loss in dementia with Lewy bodies. American Journal of Alzheimer's Disease and Other Dementias, 23, 97–102.Google Scholar

SantaCruz, K. et al. (1999). Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Neurology, 52 (Suppl 2), A476.Google Scholar

Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural Brain Research, 192, 106–113.Google Scholar

Taki, J., Yoshita, M., Yamada, M. and Tonami, N. (2004). Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Annals of Nuclear Medicine, 18, 453–461.CrossRefGoogle ScholarPubMed

Tokuda, T. et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications, 349, 162–166.Google Scholar

Weisman, D. et al. (2007). In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology, 69, 356–359.Google Scholar

Whitwell, J. L. et al. (2007). Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain, 130, 708–719.Google Scholar